News

The starting point was the recognition that technical ceramics can address several unmet medical needs. Their biocompatibility, chemical stability and wear resistance make them attractive for permanent devices and surgical tools, while calcium-phosphate ceramics such as hydroxyapatite and tricalcium phosphate can support bone regeneration and gradually be replaced by natural bone. LCM adds another decisive capability: the freedom to manufacture patient-specific geometries and precisely controlled, interconnected pore structures that would be difficult or impossible to produce conventionally.

However, design freedom alone is not enough. One of the most important lessons from working with medical-device partners is that the entire process chain must be considered from the beginning. Material formulation, printing, cleaning, debinding, sintering, inspection, documentation, packaging and sterilisation all influence the final device. This demands close cooperation between machine developers, material scientists, medical-device manufacturers, regulatory specialists and clinicians.

Long-term collaboration with partners and customers experienced in medical regulations has therefore been central to Lithoz’s approach. Projects with partners such as KLS Martin have helped move ceramic additive manufacturing from early prototypes to patient-specific implants used in real clinical workflows. Digital surgical planning based on patient imaging can be connected to a reproducible manufacturing route, allowing implants to be tailored to the defect while maintaining defined material and process standards. The result is not simply a customised shape, but a medical solution designed around surgical handling, fixation, healing and traceability.

Clinical evidence however is non-negotiable. For example; a five-year follow-up study of patient-specific beta-tricalcium-phosphate implants produced with Lithoz technology reported a total success rate above 92%, with no wound-healing problems or surgical-site infections in the monitored group. Such results demonstrate why the discussion around ceramic additive manufacturing is shifting: the technology is no longer viewed only as a promising research tool, but increasingly as a viable route for regulated medical production.

To support this transition, Lithoz has embedded medical development and production within an ISO 13485-certified quality-management system. Cleanroom material production, comprehensive quality control, documented traceability and certificates of conformity provide the reliability medical customers need when progressing from initial development towards qualification and serial production.

The wider lesson for the ceramics community is clear: adoption into any highly regulated sector is an uphill battle that is won on unprecedented quality, regulatory readiness and long-term partnerships. When these elements are developed together, 3D-printed technical ceramics can enable previously unattainable applications such as implants that are patient-specific, biologically functional and practical for real-world healthcare.

Lithoz’s new guide, “3D-Printed Ceramic Bone Replacement: Preclinical and Clinical Results,” brings this experience together. It provides a concise overview of material selection, pore architecture, bioresorption, clinical considerations and quality assurance, offering a practical starting point for anyone exploring the next generation of ceramic bone-replacement solutions.

https://lithoz.com/bone replacement

Dr. Daniel Bomze

"What inspires me most about this journey is that meaningful innovation in medicine is rarely defined by a single technological breakthrough. It is built through patience, collaboration and the willingness to address every detail; from material development and process control to regulatory requirements and clinical realities. The progress of 3D-printed ceramics shows what becomes possible when engineers, scientists, manufacturers and clinicians work toward a shared goal."

Lithoz, Austria

dbomze@lithoz.com

LinkedIn Profile